Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURATION-GC: FLOT Plus Durvalumab Neoadjuvant Followed by TS-1 Plus Durvalumab Adjuvant in Resectable Gastric Cancer
NCT07757191Phase 2Not yet recruiting
- Sponsor
- Taipei Veterans General Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Taipei Veterans General Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07757191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757191.